Navigation Links
Better understanding of neurologic defects improves post-cardiac-arrest discharge
Date:11/14/2011

Delay in initiation of therapeutic hypothermia and delay in return of spontaneous circulation (ROSC), evidenced by a palpable pulse or a measurable blood pressure, were both associated with poor neurologic outcomes in post cardiac arrest patients, according to a study being presented Nov. 14 at the at the American Heart Association (AHA) scientific sessions in Orlando, Fla. Also, caregivers who have an appropriate understanding of the patient's post cardiac arrest neurologic state could ensure better patient management at discharge.

The researchers were seeking to determine whether there were differential rates of neurologic outcomes in post cardiac patients by time to initiation, depth and duration of therapeutic hypothermia. They based the neurologic outcomes on the Cerebral Performance Category (CPC), which is ranked from 1 to 5, with 1 identified as "good," and 3 to 5 identified as poor.

"Previous studies have collapsed several CPC scores together, namely CPC 1 and 2. CPC 1 indicates the patient is conscious, alert and able to work, with only mild neurologic and psychological deficit, while with CPC 2, the patient still has sufficient cerebral function for independent activity and able to sheltered environment," explained Susan Sendelbach, RN, of the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis and researcher with Minneapolis Heart Institute Foundation.

"When you are planning discharge for patients, there is big difference between 'able to work' and 'able to work in a sheltered environment,' which really should change how we plan for discharge," she added.

Therefore, through this study, Sendelbach and her colleagues sought to further break down how the nuances of the CPC score could impact the patient and the discharge processparticularly through the separation of CPC 1 and CPC 2. Thus, they examined CPC 1, CPC 2 and CPC 3-5 independently. "We wanted to understand how the temperature management of these patients impact their neurologic outcomes," she said.

The researchers conducted a secondary data analysis from the Minneapolis Heart Institute data entered into the International Cardiac Arrest Registry (INTCAR) database in 172 adult patients who had experienced an out-of-hospital cardiac arrest undergoing therapeutic hypothermia.

The found that only two variables associated with good versus poor outcome among patients at time of ICU discharge:

  • For every five minute delay in initiating hypothermia treatment, there was a 3 percent greater odds of the patient having a poor outcome compared to a good outcome.
  • For every five minutes delay in the patient having ROSC, there is a 33 percent greater odds of the patient having a poor versus a good outcome in crude models.

"These data would support that you need to start therapeutic hypothermia as soon as possible, in addition to attempting to reach goal temperature as soon as possible in order to preserve neurologic outcomes," Sendelbach concluded.


'/>"/>

Contact: Kristin Wincek
kwincek@mhif.org
612-863-0249
Minneapolis Heart Institute Foundation
Source:Eurekalert

Related medicine news :

1. Autism-Related Hypersensitivity Better Understood
2. Developing guidelines for better reporting of health research
3. Hawaiian-shirt.net Offers 10 Tips To Beat The Winter Blues: Things You Can Do Right Now to Have a Better Day
4. Better care at any hour for palliative patients
5. Patients Do Better at Hospitals That Follow Stroke Guidelines
6. More Expensive Hospital Care May Not Mean Better
7. New MRI May Lead to Better Brain Pictures
8. Biological clock could be a key to better health, longer life
9. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
10. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
11. New approach to immune cell analysis seen as first step to better distinguish health and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: